SPY423.30+2.44 0.58%
DIA339.75+0.97 0.29%
IXIC14,256.86+115.38 0.82%

BRIEF-Voyager Therapeutics' Novel Capsids Demonstrate Robust Delivery Across Blood Brain Barrier, Widespread Cns Transduction In Non-Human Primates

05/11/2021 08:19
BRIEF-Voyager Therapeutics' Novel Capsids Demonstrate Robust Delivery Across Blood Brain Barrier, Widespread Cns Transduction In Non-Human Primates

- Voyager Therapeutics Inc VYGR.O:

  • VOYAGER THERAPEUTICS' NOVEL CAPSIDS DEMONSTRATE ROBUST DELIVERY ACROSS BLOOD BRAIN BARRIER, WIDESPREAD CNS TRANSDUCTION IN NON-HUMAN PRIMATES

  • VOYAGER THERAPEUTICS INC - A SUBSET OF CAPSIDS SHOWED A 10-FOLD OR HIGHER IMPROVEMENT IN TRANSDUCTION OF BRAIN AND SPINAL CORD, COMPARED TO AAV9

  • VOYAGER THERAPEUTICS INC - TRACER 9P801, DISPLAYED MORE THAN 1,000-FOLD HIGHER TRANSGENE EXPRESSION IN BRAIN

  • VOYAGER THERAPEUTICS INC - TRACER 9P801, DISPLAYED MORE THAN 100-FOLD HIGHER TRANSGENE EXPRESSION IN SPINAL CORD

  • VOYAGER THERAPEUTICS INC - OVERALL TOLERABILITY OF 9P801 WAS FAVORABLE AND NO TOXICITY WAS OBSERVED IN LIVER, SPINAL CORD OR DORSAL ROOT GANGLIA

  • VOYAGER THERAPEUTICS INC - IMMUNOHISTOCHEMICAL ANALYSIS INDICATED THAT 9P801 DISPLAYED PREDOMINANT NEURONAL TROPISM

  • VOYAGER THERAPEUTICS INC - IMMUNOHISTOCHEMICAL ANALYSIS INDICATED THAT 9P801 ACHIEVED WIDESPREAD TRANSDUCTION OF MULTIPLE BRAIN REGIONS

Source text for Eikon: ID:nGNX215yW

Further company coverage: VYGR.O


(([email protected];))